News from

Cancer Research

Reset All Filters
387 Results
Promising inhibitor combination for hard-to-treat leukemia subtypes
Andres Blanco in a lab at Penn Vet.

Andrés Blanco is an assistant professor of biomedical science at Penn’s School of Veterinary Medicine.

(Image: John Donges)

Promising inhibitor combination for hard-to-treat leukemia subtypes

Researchers from Penn Vet and other institutions have identified a novel inhibitor combination of molecules that induce terminal differentiation for the treatment of human non-APL subtypes of AML.

From Penn Vet

2 min. read

Enhanced CAR T cell therapy offers new strategy for lymphoma
3-D rendering of chimeric antigen receptor T (CAR-T) cell therapy, a treatment for a variety of cancers

Image: iStock/Naeblys

Enhanced CAR T cell therapy offers new strategy for lymphoma

A new study from Penn Medicine marks a significant development in the ongoing evolution of CAR T cell therapy, as a novel cytokine-enhanced CAR T that has been tested in patients with blood cancer shows robust response rates.

Meagan Raeke

2 min. read

National Academy of Sciences elects four from Penn
Four headshots of Penn Faculty. Top left tile clockwise: Mark Devlin, Katalin Karikó, E. John Wherry III, and Virginia M.Y. Lee

Four faculty have been elected to the National Academy of Sciences in recognition of their innovative contributions to original scientific research. The newly honored scholars are Mark Devlin (top left) from the School of Arts & Sciences and Katalin Karikó (top right), Virginia M.Y. Lee (bottom left), and E. John Wherry III (bottom right) from the Perelman School of Medicine.

nocred

National Academy of Sciences elects four from Penn

The newly elected members, recognized for their innovative contributions to original research, are Mark Devlin of the School of Arts & Sciences and Katalin Karikó, Virginia Lee, and E. John Wherry III of the Perelman School of Medicine.

3 min. read

Armoring CAR T cells to take on cancer
3D visualization showing a reddish-blue tumor mass with internal vasculature, surrounded by blue CAR T cells and small extracellular vesicles against a dark background.

Wei Guo of the School of Arts & Sciences and colleagues from the Perelman School of Medicine, School of Veterinary Medicine, and School of Engineering and Applied Science have teamed up to uncover how solid tumors’ complicated microenvironments can manipulate cancer-fighting CAR T cells through extracellular vesicles, causing the engineered CAR T cells to commit fratricide—essentially turning against each other instead of attacking the cancer.

(Image: iStock / Marcin Klapczynski)

Armoring CAR T cells to take on cancer

Wei Guo of the School of Arts & Sciences and colleagues from the Perelman School of Medicine, School of Veterinary Medicine, and School of Engineering and Applied Science have uncovered how solid tumors manipulate cancer-fighting CAR T cells through extracellular vesicles, causing the engineered CAR T cells to commit fratricide—essentially turning against each other instead of attacking the cancer.

3 min. read

Shelley Berger honored by AACR for cancer research

Shelley Berger honored by AACR for cancer research

Berger, the Daniel S. Och University Professor with appointments in the Perelman School of Medicine department of Cell & Developmental Biology and a Penn Integrates Knowledge Professor in the School of Arts & Sciences, is recognized for her outstanding contributions to cancer research by the American Association for Cancer Research with the 2025 AACR-Women in Cancer Research Charlotte Friend Lectureship.

New technology is poised to bring gene therapy to common chronic diseases

New technology is poised to bring gene therapy to common chronic diseases

New research from Penn Medicine reveals a safe delivery system of DNA-loaded lipid nanoparticles directly to cells, which could transform treatment for common chronic diseases like heart disease, diabetes, and cancer.

From Penn Medicine News

2 min. read

Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

A preclinical study from the Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center that combines RAS inhibition and immunotherapy shows promise for future clinical trials in pancreatic cancer treatment strategies.

Meagan Raeke

1 min. read